Skip to main content

Table 1 Characteristics of the enrolled cases

From: A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT

Variables at baseline

Total cohort (n = 614)

Training cohort (n = 457)

Validation cohort (n = 157)

G < 2 and S < 2 (n = 93)

G ≥ 2 and/or S ≥ 2 (n = 364)

p value*

Total

G < 2 and S < 2 (n = 40)

G ≥ 2 and/or S ≥ 2 (n = 117)

p value#

Total

Age (years)

41.0 (10.7)

38.3 (10.7)

41.9 (11.2)

0.02

41.2 (11.1)

39.6 (11.2)

40.79 (10.5)

0.04

40.3 (10.6)

Male gender, n (%)

422 (68.7%)

63 (67.7%)

252 (69.2%)

0.88

315 (68.9%)

27 (67.5%)

80 (68.4%)

0.99

107 (68.2%)

Height (m)

168.3 (7.5)

168.4 (7.4)

168.9 (7.5)

0.40

168.4 (7.5)

167.9 (6.5)

168.7 (7.8)

0.57

168.3 (7.4)

Weight (kg)

67.9 (12.0)

67.8 (10.5)

68.1 (12.4)

0.10

67.7 (12.2)

65.2 (12.3)

67.9 (11.9)

0.09

67.2 (12.2)

HBV DNA (log10IU/ml)

5.0 (2.2)

5.0 (2.5)

5.14 (2.0)

0.73

4.9 (2.1)

5.0 (2.6)

5.1 (2.0)

0.79

5.1 (2.0)

LS (kPa)

8.2 (4.1)

5.5 (1.5)

8.9 (4.4)

0.0001

8.3 (4.3)

4.5 (1.3)

8.9 (5.0)

0.0001

7.8 (4.6)

AFP (ng/mL)

5.2 (5.3)

5.1 (2.5)

5.9 (16.6)

0.26

5.4 (69.9)

4.7 (1.8)

4.8 (2.2)

0.31

4.8 (6.3)

GGT (IU/L)

30.8 (17.1)

31.3 (16.7)

32.4 (36.1)

0.71

31.0 (44.9)

30.3 (20.1)

30.0 (18.4)

0.62

30.1 (22.8)

TBIL (µmol/L)

16.4 (8.7)

16.9 (6.7)

17.1 (10.7)

0.05

16.2 (11.8)

15.9 (8.3)

17.2 (8.6)

0.16

16.8 (8.5)

TP (mg/L)

73.3 (7.2)

72.6 (4.6)

73.2 (7.9)

0.08

73.3 (7.0)

73.6 (4.6)

73.15 (7.9)

0.59

73.2 (7.2)

BA (µmol/L)

8.7 (13.1)

8.1 (30.6)

8.3 (11.5)

0.39

8.7 (14.7)

8.5 (21.5)

8.6 (19.2)

0.94

8.6 (8.4)

PAB (mg/L)

224.0 (48.5)

214.7 (51.6)

221.1 (48.2)

0.12

225.3 (49.6)

229.8 (46.9)

217.1 (49.8)

0.12

220.4 (49.2)

ALB (g/l)

44.4 (4.5)

45 (3.6)

44.9 (4.6)

0.40

44.5 (4.5)

44.4 (3.2)

44.05 (4.4)

0.81

44.1 (4.2)

AKP (IU/L)

74.6 (22.8)

73.0 (23.9)

75.0 (18.7)

0.06

74.8 (27.9)

73.0 (23.1)

73.5 (26.2)

0.18

73.4 (20.4)

ALT (IU/L)

43.2 (24.4)

29.7 (14.5)

48.3 (29.5)

0.0001

44.7 (14.3)

27.53 (13.2)

43.6 (18.4)

0.001

39.0 (14.5)

AST (IU/L)

35.2 (18.9)

30.6 (20.9)

35.7 (17.1)

0.05

34.7 (20.2)

32.4 (21.2)

35.6 (19.8)

0.07

36.8 (32.9)

DBIL (µmol/L)

3.1 (2.1)

3.1 (1.3)

3.2 (3.2)

0.07

3.2 (3.5)

2.7 (1.2)

3.1 (2.0)

0.18

3.0 (1.85)

PT (s)

11.7 (1.1)

11.5 (0.8)

11.8 (0.9)

0.32

11.7 (1.0)

11.6 (0.8)

11.7 (0.9)

0.71

11.7 (0.9)

INR

1.0 (0.5)

0.9 (0.1)

1.0 (0.1)

0.06

1.0 (0.1)

1.0 (0.7)

1.0 (0.7)

0.68

1.0 (0.7)

PLT (109/L)

179.6 (51.1)

183.9 (46.1)

176.6 (50.7)

0.03

178.1 (49.1)

199.6 (51.8)

179.7 (53.0)

0.04

183.9 (53.4)

HBeAg+, n (%)

348 (56.7%)

51 (54.8%)

211 (58.0%)

0.67

262 (57.3%)

22 (55.0%)

64 (54.7%)

0.99

86 (54.8%)

  1. The table shows the mean (SD) for continuous variables and number (%) for binary variables
  2. HBV hepatitis B virus, LS liver stiffness, AFP alpha fetoprotein, HBeAg hepatitis B e antigen, GGT gamma-glutamyl transpeptidase, TBIL total bilirubin, TP total protein, BA bile acid, ALB albumin, PAB prealbumin, AKP alkaline phosphatase, ALT alanine transaminase, AST aspartate aminotransferase, DBIL direct bilirubin, PT prothrombin time, INR international normalized ratio, PLT platelet
  3. *Difference of data between 2 subgroups in training cohort
  4. #Difference of data between 2 subgroups in validation cohort